Introduction {#s1}
============

Psoriatic arthritis (PsA) shares many features in common with rheumatoid arthritis (RA). For example, both diseases are characterised by the occurrence of an inflammatory arthritis in peripheral synovial joints; both respond to similar therapies including Methotrexate and anti-tumour necrosis factor biologic treatment and both are complex diseases with genetic and environmental components to susceptibility. Much progress has been made in identifying RA susceptibility genes as a result of genome-wide association studies with a recent meta-analysis listing 31 loci with confirmed evidence for association.[@R1] What is remarkable is the degree of overlap of RA loci with loci identified in other autoimmune diseases including type 1 diabetes, systemic lupus erythematosus and coeliac disease, for example.[@R2] [@R3] Those autoimmune diseases are characterised by the presence of autoantibodies and differ from PsA in that respect. However, given the overlap of clinical features between RA and PsA, it might be expected that there would be some overlap in the genetic susceptibility.

The two major RA susceptibility genes are the *HLA DRB1* and *PTPN22* genes but previous investigations have largely reported no evidence for association with PsA.[@R4]--[@R8] Few of the other loci have been investigated, to date. The aim of the current study was to investigate association of 41 suggestive and confirmed RA susceptibility loci with PsA in a large UK cohort.

Methods {#s2}
=======

Patient samples {#s3}
---------------

A total of 1057 Genomic DNA samples collected from PsA patients of White European ancestry were available via the collaboration of three UK rheumatology centres and one centre in Ireland (885 UK and 172 Ireland), details of which have been described previously.[@R9]--[@R11] PsA classification was defined as 'an inflammatory arthritis associated with psoriasis, which is usually negative for rheumatoid factor'.[@R12] This study was approved by the North West Multicentre Research Ethics Committee (MREC 99/8/84). All subjects provided informed consent.

Control samples {#s4}
---------------

Single nucleotide polymorphism (SNP) genotype data were available for healthy controls from the 1958 British Birth Cohort and the UK Blood Service Collection. Both cohorts were genotyped on the Illumina Human1M-Duo and Affymetrix Genome-wide Human SNP Array 6.0 as part of the Wellcome Trust Case-Control Consortium 2 (WTCCC2) project ([www.wtccc.org.uk](www.wtccc.org.uk)). A total of 4000 genomic DNA samples were available for in-house genotyping of SNPs not represented on these arrays.

SNP selection {#s5}
-------------

RA susceptibility SNPs were selected for genotyping if they were considered as confirmed associations or demonstrated suggestive evidence for association from a number of well-powered published reports.[@R1] [@R13]--[@R23]

Genotyping {#s6}
----------

SNP genotyping of the PsA, 1958 birth cohort and Ireland control samples was performed using Sequenom\'s MassARRAY system (San Diego, California, USA) according to the manufacturers\' specifications for the iPLEX chemistry using 10 ng of genomic DNA. Cluster plots for all SNPs were manually evaluated to confirm satisfactory performance. SNPs observed to have poor clustering characteristics were excluded from further analysis.

Statistical analysis {#s7}
--------------------

All quality control steps and statistical analyses were performed using the PLINK software package.[@R24] Missing data rates for inclusion of both SNPs and samples were set at \<10%. Test statistics for Hy--Weinberg equilibrium using an exact test, the Cochran-Armitage trend test and OR (including 95% CI) were calculated for the combined UK and Ireland dataset. To explicitly control for any bias introduced by population stratification, we analysed each population separately and combined the results via inverse-variance meta-analysis under the assumption of fixed effects. Allelic heterogeneity between the two groups was estimated using the Cochran Q and *I*[@R2] statistics. A p value of \<0.0015 was reged as statistically significant after applying a Bonferroni correction for the number of loci tested. Nominal associations were those at p \<0.05.

Subphenotype analysis was performed within the PsA dataset based on, first, the age at onset of psoriasis (type I psoriasis has an onset ≤40 years of age while type II psoriasis is defined as an onset \>40 years of age, n=354 and 540, respectively) and, second, seronegativity for rheumatoid factor (n=179) in an attempt to exclude those patients who may have PsV and coexisting RA. All subphenotype analyses were performed in UK samples only.

Results {#s8}
=======

SNP selection {#s9}
-------------

A total of 56 SNPs mapping to 41 genomic regions previously reported as suggestive or confirmed susceptibility loci for RA were selected from published reports (see online supplementary table S1).

Genotyping {#s10}
----------

Eight of the selected SNPs failed inclusion during assay design and a further five SNPs were excluded due to unsatisfactory genotype clustering. Following the removal of samples and SNPs with high levels of missing data there were a maximum of 982 PsA cases, 2925 controls from the 1958 birth cohort (genotyped in-house), 371 Ireland controls and 5380 controls from the WTCCC2 data (see online supplementary table S2).

Statistical analysis {#s11}
--------------------

Investigation of the 43 successfully genotyped SNPs identified significant association (p~trend~\<0.0015) with one SNP, rs13017599 (*REL*), in the dataset as a whole ([table 1](#T1){ref-type="table"}) and when analysis was restricted to the UK dataset (p~trend=~0.001, online supplementary table S2). The rs453211 (*PLCL2*) and rs10181656 (*STAT4*) SNPs were associated at nominal thresholds in the entire dataset (0.0016 and 0.003, respectively, [table 1](#T1){ref-type="table"}) and UK-only subgroups (p~trend=~0.009, p~trend=~0.02 respectively, online supplementary table S2). In addition, the analysis reveals nominal association (p~trend~\<0.05) to six SNPs: rs10865035 (*AFF3*), rs1980422 (*CD28*), rs2069778 (*IL2*), rs13192841 (*TNFAIP3*), rs2812378 (*CCL21*) and rs3184504 (*KIF5A*) in the combined UK and Ireland dataset but not when restricted to UK samples alone ([table 1](#T1){ref-type="table"}, online supplementary table S2). Interestingly, at three of the associated loci (*REL*, *PLCL2* and *STAT4*) the direction of the effect was opposite to that reported in the RA studies ([figure 1](#F1){ref-type="fig"}).

![OR plots for eight SNPs demonstrating evidence for association to PsA susceptibility, highlighting the opposing direction of effects for *REL*, *PLCL2* and *KIF5A*. PsA, psoriatic arthritis; RA, rheumatoid arthritis, SNP, single nucleotide ploymorphism.](annrheumdis-2011-200802fig1){#F1}

###### 

Association statistics for susceptibility to psoriatic arthritis for the 44 successfully genotype SNPs

                                 Number   MAF    Genotype counts   Genotype frequencies   HWE           p Value                           95% CI                                                     
  ------------ ---- ------------ -------- ------ ----------------- ---------------------- ------------- ---------------- ---------------- ---------------- ------- ------- ----------- ------ ------ ------
  rs2476601    1    *PTPN22*     982      5568   0.11              0.10                   15/185/782    45/991/4532      1.5/18.8/79.6    0.8/17.8/81.4    0.323   0.284   0.08863     1.14   0.98   1.34
  rs11586238   1    *CD2*        980      5750   0.24              0.23                   65/342/573    330/2036/3384    6.6/34.9/58.5    5.7/35.4/58.9    0.162   0.304   0.5419      1.04   0.93   1.16
  rs7543174    1    *IL6R*       972      5560   0.17              0.18                   25/277/670    174/1656/3730    2.6/28.5/68.9    3.1/29.8/67.1    0.647   0.586   0.2         0.92   0.81   1.05
  rs13031237   2    *REL*        972      5560   0.34              0.38                   115/431/426   781/2617/2162    11.8/44.3/43.8   14.0/47.1/38.9   0.721   0.819   0.002569    0.86   0.77   0.95
  rs13017599   2    *REL*        971      5553   0.33              0.38                   107/436/428   781/2612/2160    11.0/44.9/44.1   14.1/47.0/38.9   0.829   0.864   0.0005242   0.84   0.75   0.93
  rs1160542    2    *AFF3*       981      5568   0.47              0.46                   229/472/280   1157/2798/1613   23.3/48.1/28.5   20.8/50.3/29.0   0.277   0.388   0.2194      1.06   0.96   1.17
  rs10865035   2    *AFF3*       981      3296   0.48              0.46                   237/472/272   667/1678/951     24.2/48.1/27.7   20.2/50.9/28.9   0.250   0.150   0.04775     1.11   1.00   1.22
  rs10181656   2    *STAT4*      980      3832   0.25              0.22                   67/359/554    180/1327/2325    6.8/36.6/56.5    4.7/34.6/60.7    0.397   0.638   0.003032    1.19   1.06   1.34
  rs1980422    2    *CD28*       975      5747   0.25              0.23                   54/372/549    273/2051/3423    5.5/38.2/56.3    4.8/35.7/59.6    0.437   0.131   0.0471      1.12   1.00   1.25
  rs231775     2    *CTLA4*      971      5568   0.39              0.39                   144/468/359   852/2675/2041    14.8/48.2/37.0   15.3/48.0/36.7   0.686   0.633   0.7419      0.98   0.89   1.09
  rs3087243    2    *CTLA4*      978      5748   0.43              0.44                   162/511/305   1126/2850/1772   16.6/52.2/31.2   19.6/49.6/30.8   0.037   0.749   0.1609      0.93   0.85   1.03
  rs4535211    3    *PLCL2*      975      5745   0.53              0.49                   262/503/210   1376/2857/1512   26.9/51.6/21.5   24.0/49.7/26.3   0.304   0.712   0.001663    1.17   1.06   1.28
  rs13315591   3    *FAM107A*    973      5740   0.09              0.08                   6/164/803     37/878/4825      0.6/16.9/82.5    0.6/15.3/84.1    0.560   0.729   0.2671      1.10   0.93   1.30
  rs874040     4    *RBPJ*       972      5704   0.32              0.30                   100/423/449   511/2404/2789    10.3/43.5/46.2   9.0/42.1/48.9    1.000   0.850   0.0736      1.10   0.99   1.22
  rs2069778    4    *IL2*        960      3699   0.16              0.18                   19/269/672    124/1086/2489    2.0/28.0/70.0    3.4/29.4/67.3    0.229   0.697   0.03611     0.87   0.76   0.99
  rs6822844    4    *IL21*       958      5549   0.16              0.17                   20/264/674    155/1631/3763    2.1/27.6/70.4    2.8/29.4/67.8    0.396   0.178   0.07937     0.89   0.78   1.02
  rs10040327   5    *ANKRD55*    970      5737   0.10              0.12                   7/186/777     102/1139/4496    0.7/19.2/80.1    1.8/19.9/78.4    0.300   0.004   0.07912     0.87   0.74   1.01
  rs26232      5    *C5orf30*    972      5558   0.32              0.33                   95/430/447    575/2511/2472    9.8/44.2/46.0    10.3/45.2/44.5   0.606   0.095   0.3614      0.95   0.86   1.06
  rs548234     6    *PRDM1*      980      5751   0.31              0.33                   92/423/465    604/2599/2548    9.4/43.2/47.4    10.5/45.2/44.3   0.823   0.129   0.06098     0.91   0.82   1.01
  rs13207033   6    *TNFAIP3*    960      5723   0.26              0.28                   63/371/526    451/2260/3012    6.6/38.6/54.8    7.9/39.5/52.6    0.867   0.355   0.1154      0.92   0.82   1.02
  rs6920220    6    *TNFAIP3*    959      5723   0.21              0.22                   48/312/599    289/1968/3466    5.0/32.5/62.5    5.0/34.4/60.6    0.385   0.647   0.3449      0.94   0.84   1.06
  rs5029937    6    *TNFAIP3*    956      3447   0.03              0.03                   2/52/902      5/229/3213       0.2/5.4/94.4     0.1/6.6/93.2     0.191   0.607   0.2508      0.84   0.63   1.13
  rs394581     6    *TAGAP*      978      2988   0.32              0.31                   102/417/459   298/1271/1419    10.4/42.6/46.9   10.0/42.5/47.5   0.606   0.580   0.6767      1.02   0.92   1.14
  rs3093023    6    *CCR6*       968      5735   0.42              0.43                   146/523/299   1099/2778/1858   15.1/54.0/30.9   19.2/48.4/32.4   0.001   0.295   0.29        0.95   0.86   1.05
  rs42041      7    *CDK6*       982      5747   0.26              0.25                   62/387/533    342/2144/3261    6.3/39.4/54.3    6.0/37.3/56.7    0.507   0.696   0.1781      1.08   0.97   1.20
  rs10488631   7    *IRF5*       973      5559   0.11              0.11                   14/194/765    59/1085/4415     1.4/19.9/78.6    1.1/19.5/79.4    0.635   0.444   0.4412      1.06   0.91   1.24
  rs2736340    8    *BLK*        971      5741   0.24              0.25                   50/373/548    330/2158/3253    5.1/38.4/56.4    5.7/37.6/56.7    0.222   0.269   0.8585      0.99   0.89   1.11
  rs2812378    9    *CCL21*      960      5723   0.37              0.34                   138/433/389   643/2615/2465    14.4/45.1/40.5   11.2/45.7/43.1   0.332   0.206   0.01475     1.13   1.02   1.25
  rs951005     9    *CCL21*      973      5558   0.16              0.15                   27/249/697    111/1406/4041    2.8/25.6/71.6    2.0/25.3/72.7    0.394   0.421   0.2876      1.08   0.94   1.23
  rs10760130   9    *TRAF1/C5*   959      5549   0.44              0.44                   189/466/304   1089/2680/1780   19.7/48.6/31.7   19.6/48.3/32.1   0.694   0.164   0.8523      1.01   0.92   1.11
  rs2900180    9    *TRAF1/C5*   982      5570   0.35              0.35                   120/445/417   706/2479/2385    12.2/45.3/42.5   12.7/44.5/42.8   0.944   0.118   0.9659      1.00   0.90   1.10
  rs706778     10   *IL2RA*      965      5740   0.42              0.40                   193/432/340   936/2737/2067    20.0/44.8/35.2   16.3/47.7/36.0   0.010   0.564   0.06669     1.10   0.99   1.21
  rs2104286    10   *IL2RA*      980      5743   0.27              0.28                   73/390/517    462/2297/2984    7.4/39.8/52.8    8.0/40.0/52.0    1.000   0.493   0.5272      0.97   0.87   1.08
  rs11594656   10   *IL2RA*      976      5749   0.23              0.24                   66/320/590    342/2087/3320    6.8/32.8/60.5    5.9/36.3/57.7    0.015   0.564   0.3705      0.95   0.85   1.06
  rs4750316    10   *PRKCQ*      982      5749   0.17              0.19                   24/290/668    222/1745/3782    2.4/29.5/68.0    3.9/30.4/65.8    0.313   0.248   0.0562      0.88   0.78   1.00
  rs540386     11   *TRAF6*      973      5736   0.14              0.13                   24/215/734    101/1327/4308    2.5/22.1/75.4    1.8/23.1/75.1    0.098   0.955   0.8234      1.02   0.88   1.17
  rs1678542    12   *KIF5A*      958      5723   0.42              0.39                   184/434/340   896/2675/2152    19.2/45.3/35.5   15.7/46.7/37.6   0.034   0.182   0.02048     1.13   1.02   1.24
  rs3184504    12   *SH2B3*      963      5555   0.50              0.49                   248/467/248   1298/2819/1438   25.8/48.5/25.8   23.4/50.7/25.9   0.367   0.248   0.305       1.05   0.95   1.16
  rs7234029    18   *PTNP2*      972      5731   0.17              0.16                   24/273/675    128/1536/4067    2.5/28.1/69.4    2.2/26.8/71.0    0.642   0.249   0.3219      1.07   0.94   1.22
  rs4810485    20   *CD40*       960      5723   0.25              0.24                   66/354/540    332/2088/3303    6.9/36.9/56.2    5.8/36.5/57.7    0.443   0.942   0.2308      1.07   0.96   1.20
  rs11203203   21   *UBASH3A*    966      5731   0.35              0.37                   119/440/407   786/2696/2249    12.3/45.5/42.1   13.7/47.0/39.2   1.000   0.651   0.07026     0.91   0.82   1.01
  rs3218258    22   *IL2RB*      979      5569   0.27              0.26                   76/379/524    381/2161/3027    7.8/38.7/53.5    6.8/38.8/54.4    0.518   0.890   0.4175      1.05   0.94   1.17
  rs743777     22   *IL2RB*      960      5723   0.33              0.31                   100/431/429   549/2450/2724    10.4/44.9/44.7   9.6/42.8/47.6    0.609   0.975   0.102       1.09   0.98   1.21

Chr, chromosome; HWE, Hy--Weinberg equilibrium; MAF, minor allele frequency; SNP, single nucleotide polymorphism.

Subphenotype analysis revealed a greater effect for the *REL* SNP, rs13017599, in the late onset psoriasis (type II) and the seronegative subgroups of PsA (see online supplementary table S3). Conversely, the association to the *PLCL2* SNP, rs453211, was wholly restricted to the early onset psoriasis subgroup (type I) (see online supplementary table S3). While these associations are intriguing, their interpretation should be tempered by acknowledging the limited number of samples in these subgroups.

Discussion {#s12}
==========

We have undertaken a comprehensive analysis testing established RA susceptibility loci for association with PsA. We have found significant evidence for association with the *REL* locus and nominal evidence for association with seven other RA susceptibility SNPs. Interestingly, for three of the eight PsA-associated variants, the risk allele is opposite to that reported in RA.

Given the phenotypic similarities between RA and PsA, it was expected that some genetic overlap would be observed as the concept is well established for autoimmune diseases such as RA, systemic lupus erythematosus and type 1 diabetes.[@R2] [@R3] However, it could also be argued that inflammatory arthritis may be an outcome of different immune responses in joints caused by different triggers with different underlying genetic susceptibility. Indeed, enthesitis is thought to be the primary abnormality in PsA by many researchers, with synovitis being a secondary phenomenon, in contrast to RA where the synovitis takes primacy. The results of this genetic study support a mixed picture of genetic overlap between RA and PsA, with some RA loci showing association with the same allele, some with the opposite allele and some showing no association with PsA.

Association of different autoimmune diseases with opposite alleles of the same susceptibility variant has been reported previously. For example, the minor T allele of the *PTPN22* rs2476601 SNP confers susceptibility to RA, type 1 diabetes and autoimmune thyroid disease while the major C allele confers susceptibility to Crohn\'s disease.[@R25] Similarly, association at the *REL* locus SNP, rs13017599, has been reported previously in psoriasis but the opposite allele has also been associated with RA.[@R26] [@R27] These findings may suggest that RA clusters with the classical autoantibody associated autoimmune diseases, while PsA shares greater genetic similarity to psoriasis and seronegative diseases, such as Crohn\'s disease. It is possible that these SNPs may be markers for susceptibility to psoriasis and not specific to PsA. It would be of great interest to test these markers in a cohort of psoriasis patients screened to exclude samples with evidence of inflammatory arthritis.

The conclusions that can be drawn are necessarily limited by the limitations of the study design. Many of the RA susceptibility loci examined have modest effect sizes that the current study was underpowered to reliably detect online supplementary table S1. It may be that more RA susceptibility loci are associated with PsA than detected currently, therefore. For example, the study had only limited power to detect association at a number of the loci. This power is further reduced by using a Bonferroni corrected p value threshold and so there may be a number of false negative results. For this reason, we have reported loci showing nominal as well as significant evidence for association although replication is required for all these SNPs in additional datasets before they can be confidently labelled as PsA susceptibility loci. Ultimately, a full understanding of the extent of overlap between PsA and RA susceptibility loci will require comparison of well-powered genome-wide association studies in the two diseases.

A further limitation of the study design is the testing of only one or a small number of variants at each locus. It may be that different variants at the locus are more strongly associated with PsA; for example, different variants at the *TNFAIP3* gene are associated with systemic lupus erythematosus, RA and psoriasis.[@R18][@R28]--[@R31] Investigation of this possibility will require analysis of detailed fine mapping data of RA associated genomic loci in PsA samples.

The strongest evidence for association was with the *REL* locus where two SNPs showed association but only one remained significant at the corrected threshold (rs13017599). The *REL* locus, which encodes c-REL, a member of the NFκB inflammatory pathway, has been reported to be associated with type I psoriasis in a large genome-wide association study but with a different SNP, rs702873 (OR 1.12).[@R27] There is strong, but not complete, correlation (r[@R2]=0.76 with rs13017599) between the two variants suggesting that the primary association is with psoriasis rather than PsA. The robust identification of PsA specific variants would require a collection of patients with uncomplicated psoriasis, where patients have been screened for the absence of inflammatory arthritis. Unfortunately, such a collection is not currently available to our research group.

Interestingly, the subphenotype analysis in the PsA samples suggests that the association may be even stronger in type II psoriasiscompared with the cohort as a whole (OR 1.47 vs 1.19, based on allele G as the risk allele) but this requires confirmation in other cohorts.

Association with *PLCL2* has not been reported previously with psoriasis and it shows only borderline evidence for association in the current study when using the Bonferroni corrected p value. Furthermore, association of this locus with RA remains suggestive rather than confirmed at genome-wide significance thresholds and hence this result may represent a false positive finding. Nonetheless, it is of interest because the gene encodes a negative regulator of B cell receptor signalling, important in controlling immune responses and, again, the allele conferring risk to RA is protective for PsA.[@R1] [@R15]

Of the other loci with nominal evidence for association, *STAT4* has been reported to be associated with psoriasis previously in a Greek population.[@R32] The reported SNP, rs7574865, is highly correlated with rs10181656 reported in this study (r[@R2]=1.00). Interestingly, the allele associated with RA susceptibility conferred protection to PsA. Association at the *IL2/21* locus has been reported previously with a different SNP (rs13151961 r[@R2]=1.00) in a US PsA cohort[@R33] and with the same SNP in a UK psoriasis cohort.[@R34]

An important point is that the majority of RA risk loci are identified using patients positive for anticyclic citrullinated peptide antibodies. Given the importance of seronegativity in the classification of PsA, it would be interesting to evaluate susceptibility risk loci identified in anticyclic citrullinated peptide antibody negative RA samples. However, to date there are no robustly confirmed susceptibility loci for seronegative RA

In summary, we report significant evidence for association of the *REL* locus with PsA and nominal evidence for association with eight other RA associated SNPs. For a significant minority of the loci, opposing alleles confer risk to PsA and RA suggesting that there are fundamental differences in the aetiological mechanisms underlying these two types of inflammatory arthritis.
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